Effect of Bifidobacterium Lactobacillus Triple Viable Capsules Combined with Mesalazine in the Treatment of Ulcerative Colitis
Objective To explore the efficacy of bifidobacterium lactobacillus triple viable capsules combined with mesalazine in the treatment of ulcerative colitis.Methods A total of 98 patients with ulcerative colitis admitted to Lantian County People's Hospital from June 2018 to June 2023 were selected as the study subjects.All patients were divided into an observation group(61 cases)and a control group(37 cases)based on different treatment plans.The observation group was treated with a combination of mesalazine and bifidobacterium lactobacillus triple viable capsules,while the control group was treated with mesalazine.Compare the efficacy and adverse reactions of two groups,as well as the intestinal mucosal barrier function,gut microbiota count,and immune function before and after treatment.Results The total clinical effective rate of the observation group was 95.08%,which was significantly higher than the control group's 78.38% (P<0.05).After treatment,the intestinal mucosal barrier function,gut microbiota count,and immune function indicators in the observation group were significantly better than before treatment,and the above indicators in the observation group were significantly better than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of the combination of Bifidobacterium lactobacillus triple viable capsules and mesalazine in the treatment of ulcerative colitis is more ideal and worthy of clinical promotion and use.
Ulcerative ColitisMedicationMesalazineProbioticsBifidobacterium Lactobacillus Triple Live CapsuleEffect
NETL
NSTL
万方数据
